All In Biotech

Drug Trial Radar · NCT05442788

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

A Phase Ib, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HB0017 Following Multiple Dose in Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Jul 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Sep 2, 2021

Primary completion

May 31, 2022

Study completion May 31, 2022

Sponsor

Lead sponsor
Huabo Biopharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • HB0017 150mg or matching placeboBiological

    Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.

  • HB0017 300mg or matching placeboBiological

    Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.

  • HB0017 450mg or matching placeboBiological

    Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent AE/SAEsTime frame: From baseline through week 20
  2. Elimination half-life (T1/2)Time frame: From baseline through week 20
  3. Area under drug-time curve (AUC)Time frame: From baseline through week 20
  4. Total clearance (CL/F)Time frame: From baseline through week 20
  5. Maximum serum concentrations (Cmax)Time frame: From baseline through week 20
  6. Mean retention time (MRT)Time frame: From baseline through week 20
  7. Volume of distribution (Vz/F)Time frame: From baseline through week 20
  8. Peak time(Tmax)Time frame: From baseline through week 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.